VOR
HealthcareVor Biopharma Inc.
$10.58
$-1.06 (-9.11%)
Jan 5, 2026
Price History (1Y)
Analysis
Vor Biopharma Inc. is a biotechnology company within the healthcare sector, with a market capitalization of $231.81 million and 154 employees. The company's financial health is marked by significant losses, with net income totaling -$2,449,551,104 over the trailing twelve months. EBITDA stands at -$333,558,016, while free cash flow amounts to -$183,391,376. Notably, the company's gross margin, operating margin, and profit margin are all 0.0%. Return on assets (ROA) is -144.3%, indicating substantial losses relative to assets. The valuation context for Vor Biopharma Inc. includes a forward P/E ratio of -1.70, suggesting a loss-making period. The price-to-book ratio is -0.04, and the enterprise value to EBITDA ratio is 0.14. The company's cash balance stands at $170.46 million, while debt totals $3.06 million, resulting in a current ratio of 9.16.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Vor Biopharma Inc.
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $231.81M
- P/E Ratio
- N/A
- 52-Week High
- $65.80
- 52-Week Low
- $2.62
- Avg Volume
- 1.67M
- Beta
- 2.02
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 154